| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.048 | 0.4 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.031 | 0.4 |